What is the 13F Pro Quality Score for PGNY?

13F Pro ranks Progyny, Inc. (PGNY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PGNY's current score at https://13fpro.ai/research/PGNY (free sign-up required for the full ranking).

Which hedge funds own the most PGNY stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PGNY include BlackRock,, FMR, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PGNY as soon as new 13F filings post.

Where does 13F Pro source PGNY data?

All Progyny, Inc. fundamentals and ownership data come directly from SEC EDGAR. Progyny, Inc. files with the SEC under CIK 1551306. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PGNY in?

Progyny, Inc. (PGNY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PGNY research updated on 13F Pro?

PGNY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Progyny, Inc.(PGNY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1551306 PGNY stock profile & AI dashboard →

13F Pro Quality Score

59.0/100

Rank #948 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

62.3/100

Profitability

56.4/100

Balance Sheet

85.5/100

Earnings Quality

44.5/100

Free Cash Flow

71.4/100

Institutional Flow

12.0/100

Revenue Scale

54.0/100

Dilution Risk

16.6/100

PGNY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Progyny, Inc. (PGNY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGNY at 59.0/100 on a 32-signal composite quality model, placing it at rank #948 of 2,879 stocks — the top half of the AI-ranked universe. PGNY scores in the top quartile across balance sheet strength (85.5). Areas of concern include institutional flow (12.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Progyny, Inc. reports quarterly revenue of $328.5M, net income of $24.2M, an operating margin of 10.8%. Top institutional holders of PGNY by reported 13-F value include BlackRock,, FMR, STATE STREET, based on the most recent SEC filings. PGNY trades on the Nasdaq exchange and files with the SEC under CIK 1551306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Progyny, Inc. directly from SEC EDGAR. Progyny, Inc.'s 13F Pro composite quality score has ranged between 8 and 83 since 2022, currently 59.0 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about Progyny, Inc.

Quirks, history, and lore behind PGNY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Annual revenue in the range of roughly $1 billion, built almost entirely on contracts with self-insured employers who want to offer richer benefits.
3
The History
Founded in the late 2010s, it went public around 2019 — one of the few healthcare IPOs of that era centered entirely on a single benefits category.
4
The Secret
It doesn't own clinics or employ doctors — it's a benefits management platform that builds curated networks of specialists and handles all the authorization and payment.
5
The Lore
Its clients include some of the largest companies in America, yet most employees only discover it exists when they open their HR benefits portal and see a dedicated fertility benefit for the first time.
6
The Giveaway
This company is essentially the go-to fertility benefits manager for big employers — covering IVF, egg freezing, and surrogacy so that workers don't have to fight with a generic insurer over every treatment cycle.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$328.5M

Net Income

Q1 2026

$24.2M

Free Cash Flow

Q1 2026

$39.6M

Operating Margin

Q1 2026

10.8%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.4% YoY

$1.29BFY 2025

FY20 $344.9MFY21 $500.6MFY24 $1.17BFY25 $1.29B

Net Income

+7.7% YoY

$58.5MFY 2025

FY20 $46.5MFY21 $65.8MFY24 $54.3MFY25 $58.5M

Operating Income

+26.4% YoY

$85.3MFY 2025

FY20 $8.3MFY21 $32.3MFY24 $67.5MFY25 $85.3M

EPS (Diluted)

+14.0% YoY

$0.65FY 2025

FY20 $0.47FY21 $0.66FY24 $0.57FY25 $0.65

Total Assets

+22.3% YoY

$742.4MFY 2025

FY20 $253.9MFY21 $358.1MFY24 $607.1MFY25 $742.4M

Total Debt

—FY 2025

FY20 —FY21 —FY24 —FY25 —

Op. Cash Flow

+17.4% YoY

$210.2MFY 2025

FY20 $36.2MFY21 $26.0MFY24 $179.1MFY25 $210.2M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2018	FY 2017
Revenue	$1.29B +10.4%	$1.17B +133.2%	$500.6M +45.2%	$344.9M +227.2%	$105.4M +116.9%	$48.6M
Net Income	$58.5M +7.7%	$54.3M -17.4%	$65.8M +41.6%	$46.5M +6928.6%	$661.0K +105.3%	$-12.5M
Operating Income	$85.3M +26.4%	$67.5M +108.6%	$32.3M +287.4%	$8.3M +341.8%	$-3.5M +68.6%	$-11.0M
EPS (Diluted)	$0.65 +14.0%	$0.57 -13.6%	$0.66 +40.4%	$0.47 +2250.0%	$0.02 +101.7%	$-1.19
Total Assets	$742.4M +22.3%	$607.1M +69.6%	$358.1M +41.0%	$253.9M +514.5%	$41.3M	—
Total Debt	—	—	—	—	$253.0K	—
Operating Cash Flow	$210.2M +17.4%	$179.1M +587.9%	$26.0M -28.1%	$36.2M +1493.4%	$2.3M +124.0%	$-9.5M

AI Insight: PGNY Financial Trends

Progyny's Q1 2026 operating income surged to $35M — the highest in the 8-quarter dataset — while net income hit a new peak of $24M.

• Operating income jumped from $15M in Q4 2025 to $35M in Q1 2026, the strongest quarterly result across the entire period.

• Revenue grew 9.5% year-over-year from $304M in Q2 2024 to $333M in Q2 2025, with Q1 2026 at $329M sustaining that elevated level.

• Net income of $24M in Q1 2026 nearly doubled Q4 2025's $12M, suggesting meaningful margin expansion in the latest quarter.

⚠ Equity fell sharply from $560M in Q3 2025 to $439M in Q1 2026 — a $121M drop worth monitoring for capital return or impairment drivers.

⚠ Operating cash flow dipped to $46M in Q1 2026 despite record operating income — divergence between accrual earnings and cash generation warrants scrutiny.

⚠ Seasonal Q3/Q4 softness is consistent across both 2024 and 2025; whether Q1 2026 strength holds through mid-year is a key inflection to track.

AI Insight: PGNY Ratio Trends

Q1 2026 marks a decisive profitability inflection, with operating margin surging to 10.8% and ROIC hitting 32.2% — both series highs in the dataset.

• Operating margin jumped from 4.8% in Q4 2025 to 10.8% in Q1 2026, the highest reading across all reported quarters.

• ROIC rebounded sharply to 32.2% in Q1 2026, recovering from a trough of 11.5% in Q3 2024 and 11.8% in Q4 2025.

• ROA expanded to 13.9% in Q1 2026 versus 6.7% in Q4 2025, with ROE reaching 22.1% — up from 9.7%.

• A consistent Q3/Q4 seasonal dip in margins is visible in both 2024 and 2025, suggesting cyclical rather than structural pressure.

⚠ Q3 and Q4 margins have compressed materially in each of the last two years; watch whether Q3 2026 repeats this seasonal deterioration.

⚠ D/E data is absent across all periods, leaving leverage and balance-sheet risk unassessable from this dataset.

⚠ TTM ROIC of 22.0% lags the Q1 2026 annualized 32.2%, confirming the spike is recent — durability requires confirmation next quarter.

Get alerted when PGNY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Progyny, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PGNY

BlackRock, Inc.
$203.7M11,998,467 sh
FMR LLC
$110.4M6,500,819 sh
STATE STREET CORP
$52.3M3,080,293 sh
AMERIPRISE FINANCIAL INC
$48.0M2,825,331 sh
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/
$45.7M2,693,393 sh
MORGAN STANLEY
$38.8M2,287,617 sh
WELLINGTON MANAGEMENT GROUP LLP
$38.8M2,287,381 sh
Soleus Capital Management, L.P.
$35.1M2,067,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$34.7M2,042,965 sh
DIMENSIONAL FUND ADVISORS LP
$26.7M1,573,425 sh

Fund	Value	Shares
BlackRock, Inc.	$203.7M	11,998,467
FMR LLC	$110.4M	6,500,819
STATE STREET CORP	$52.3M	3,080,293
AMERIPRISE FINANCIAL INC	$48.0M	2,825,331
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/	$45.7M	2,693,393
MORGAN STANLEY	$38.8M	2,287,617
WELLINGTON MANAGEMENT GROUP LLP	$38.8M	2,287,381
Soleus Capital Management, L.P.	$35.1M	2,067,000
GEODE CAPITAL MANAGEMENT, LLC	$34.7M	2,042,965
DIMENSIONAL FUND ADVISORS LP	$26.7M	1,573,425

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PGNY on your watchlist

Track score changes the day Progyny, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PGNY a good stock to buy?

13F Pro's AI-powered analysis of Progyny, Inc. (PGNY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PGNY are available on the PGNY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PGNY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PGNY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Progyny, Inc.'s investment landscape.